A Workers’ Comp Drug Is Listed as “Exempt.” Does It Still Need Approval?

“Exempt” on California’s workers’ compensation drug list does not mean that every prescription containing that ingredient can be dispensed without prior review. The general exemption applies when treatment follows the Medical Treatment Utilization Schedule, or MTUS. Brand-name restrictions, physician dispensing, compounded drugs and some off-label uses require separate checks.

The useful first question is therefore not simply “Is the drug on the list?” It is “Does this exact prescription, for this use and dispensing arrangement, qualify for the exemption?” The physician supplies the clinical explanation. The worker should not change or stop medication based on a list entry or this article.

Match the actual prescription to the operative list

The MTUS Drug List is organized by active ingredients. Identify the drug’s ingredients, formulation, strength, brand or generic status, intended use and dispenser. A combination product not listed as a combination is an unlisted drug even if its separate ingredients appear on the list. Unlisted drugs generally require authorization through prospective review before dispensing. Title 8, section 9792.27.10(a) and (e).

The DWC’s official formulary orders and updates identify the operative versions, including Drug List version 14 effective April 30, 2026. Use the applicable list and its notes rather than an undated screenshot, a commercial label saying a drug is covered, or a different insurer’s formulary.

A Non-Exempt designation generally means prospective authorization is needed, with expedited review when warranted by the worker’s condition. Special Fill and Perioperative Fill are separately defined exceptions with their own conditions; a label on the list is not enough to establish that a particular fill meets them. Section 9792.27.10(c)–(d).

“Exempt” still depends on guideline-consistent treatment

Section 9792.27.10(b) allows an Exempt drug to be dispensed without prospective authorization when treatment accords with the MTUS Treatment Guidelines, subject to the listed exceptions. The active ingredient’s status does not independently establish that the indication, treatment plan or patient-specific use fits those guidelines.

Ask the treating office which guideline recommendation applies and whether the prescription meets its conditions. If a dispute concerns why treatment outside a recommendation is medically necessary, the physician needs to address the governing evidence framework. A worker’s statement that a medication previously helped can be useful history, but it does not replace that medical explanation.

Four prescription details can change the authorization answer

Off-label use: Off-label does not always mean prior authorization is required. An Exempt drug may be dispensed without prospective review for an off-label use recommended by the MTUS guideline. Prior review is required for an Exempt drug lacking that recommendation for the intended off-label use, and for Non-Exempt or unlisted drugs used off-label. Section 9792.27.5.

A brand when a less costly equivalent generic exists: If the physician specifies “Do Not Substitute” or “Dispense as Written” in the circumstances covered by the rule, patient-specific medical necessity must be documented in the chart and the specified treating report. The physician must submit a Request for Authorization and obtain prospective approval before the brand is dispensed. The ingredient’s Exempt designation does not eliminate that step. Section 9792.27.7.

Physician dispensing: Drugs dispensed by a physician generally require prospective authorization. One exception permits up to a seven-day supply of Exempt drugs consistent with the MTUS guidelines at an initial visit occurring within seven days of injury. The timing of the visit and size of the supply both matter. Special Fill and Perioperative Fill provisions may also apply in their specified circumstances. Network and pharmacy-benefit restrictions remain relevant. Section 9792.27.8.

Compounded drugs: Prospective authorization is required even if an ingredient is Exempt. The physician must document patient-specific medical necessity for the compounded preparation instead of the alternatives described in the rule and submit an RFA. The rule also preserves specified network and pharmacy-benefit restrictions. Section 9792.27.9.

Separate an authorization objection from a medical-necessity denial

If a pharmacy or administrator says approval is missing, ask for the precise reason and obtain the complete written notice. Is the objection that a brand or compounded preparation needed prior authorization? Is the use outside the guideline recommendation? Is medical necessity disputed, or is there a separate claim-liability issue?

Those questions affect the review route. Section 9792.27.17 assigns medical-necessity disputes to the UR/IMR framework and distinguishes other failures to follow formulary rules, which use the specified expedited-hearing procedure. It is not safe to assume that every pharmacy rejection is the same kind of UR denial.

Keep the prescription, ingredient and formulation details, treating report or RFA, denial or rejection, delivery dates and the list version used. Our worker’s treatment-denial checklist explains the later notice-and-response task. A request to clarify the reason does not itself preserve a review deadline.

A scheduled advisory meeting does not change a prescription’s status

DWC announced a Pharmacy and Therapeutics Committee meeting for October 21, 2026 in its September 15 notice. A meeting announcement is not an adopted drug-list change or a report of an outcome. Check an actual operative order before treating a proposed or discussed change as effective.

For a current access problem, the immediate review remains prescription-specific: Which rule applies, what documentation exists, what the administrator actually disputed and which deadline governs the response. The workers’ compensation practice can review that packet while the treating physician addresses the medical plan.